Drugs Containing Excipient (Inactive Ingredient) MONOSODIUM GLUTAMATE

« Back to Dashboard

Generic drugs containing MONOSODIUM GLUTAMATE excipient

Company	Ingredient	NDC	Excipient
Merck Sharp & Dohme LLC	measles, mumps, rubella and varicella virus vaccine live	0006-4171	MONOSODIUM GLUTAMATE
Merck Sharp & Dohme LLC	varicella virus vaccine live	0006-4826	MONOSODIUM GLUTAMATE
Merck Sharp & Dohme Corp	zoster vaccine live	0006-4963	MONOSODIUM GLUTAMATE
MedImmune LLC	influenza vaccine live intranasal	66019-112	MONOSODIUM GLUTAMATE
MedImmune LLC	influenza vaccine live intranasal	66019-113	MONOSODIUM GLUTAMATE

Monosodium Glutamate Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: October 16, 2026

Monosodium glutamate, or MSG, is primarily a high-volume food and fermentation product rather than a standalone pharmaceutical excipient market. Its pharmaceutical relevance is concentrated in formulation support, flavor masking, amino-acid nutrition, fermentation media, and certain biological or parenteral manufacturing processes. Public companies generally do not report pharmaceutical-grade MSG revenue separately, so the financial outlook depends on broader glutamate, amino-acid, food-additive, and bioprocessing segments.

The market is structurally competitive, price-sensitive, and concentrated in Asia. China remains the largest production base. Ajinomoto, Fufeng Group, Meihua Holdings, CJ CheilJedang, and Vedan are among the major producers or commercial participants in MSG and related amino acids. The strongest growth drivers are pharmaceutical and biopharmaceutical manufacturing demand, expansion of injectable and nutrition products, fermentation capacity, and demand for traceable, compendial-quality excipients. The main constraints are limited pharmaceutical-grade demand, low switching costs, commodity pricing, sodium exposure, and competition from other amino acids and formulation agents.

What is monosodium glutamate and how is it used in pharmaceutical manufacturing?

Monosodium glutamate is the sodium salt of L-glutamic acid. Its chemical formula is C5H8NO4Na, and its CAS Registry Number is 142-47-2. Commercial MSG is commonly produced through microbial fermentation of carbohydrate feedstocks, followed by purification, crystallization, drying, and particle-size control.

In pharmaceutical manufacturing, MSG has several potential roles:

Application	Role of MSG	Commercial relevance
Oral formulations	Flavor modifier and taste-masking agent	Limited but useful in bitter formulations
Amino-acid products	Nitrogen and amino-acid source	Relevant to nutrition and specialty formulations
Bioprocessing	Fermentation nutrient or media component	More important in manufacturing than in finished dosage forms
Biological products	Process ingredient or stabilizing component in selected systems	Requires product-specific validation
Research reagents	Cell-culture or microbial-growth component	Small but recurring demand
Food-pharmaceutical interface	Ingredient in medical nutrition and oral-care products	Larger than conventional tablet-excipient demand

MSG is not generally a primary binder, disintegrant, lubricant, preservative, or controlled-release polymer. Its value is therefore based on functional contribution in selected formulations rather than broad substitution across oral solid-dose products.

The principal commercial distinction is between food-grade MSG and pharmaceutical or bioprocess-grade material. Pharmaceutical customers may require tighter limits for elemental impurities, microbial contamination, endotoxins, residual solvents, particle-size distribution, and batch traceability than ordinary food applications.

What regulatory status does monosodium glutamate have as a pharmaceutical excipient?

MSG has a long regulatory history as a food ingredient. In the United States, monosodium glutamate is recognized as a direct food ingredient under FDA regulations, subject to applicable specifications and labeling requirements.[1] That status does not automatically establish acceptance for every pharmaceutical dosage form.

For pharmaceutical use, the relevant assessment is product-specific. Drug manufacturers typically evaluate:

• Identity and assay
• Related substances and degradation products
• Heavy metals and elemental impurities
• Microbial limits
• Endotoxin levels where applicable
• Residual solvents
• Particle size and morphology
• Sodium contribution
• Compatibility with the active pharmaceutical ingredient
• Stability under the intended storage conditions

The United States Pharmacopeia-National Formulary, European Pharmacopoeia, Japanese Pharmacopoeia, and Food Chemicals Codex may provide relevant quality standards depending on the grade and market. A buyer must confirm the exact monograph, supplier specification, and intended route of administration before treating a food-grade material as a pharmaceutical excipient.

The FDA Inactive Ingredient Database is the principal U.S. reference for prior use of inactive ingredients in approved drug products.[2] A listed inactive ingredient does not provide blanket approval for all routes, strengths, or dosage forms. Route-specific precedent and maximum potency remain relevant.

Is monosodium glutamate listed in the Orange Book?

MSG is not an Orange Book-listed active pharmaceutical ingredient. The FDA Orange Book identifies approved drug products, active ingredients, dosage forms, sponsors, patents, and regulatory exclusivities for qualifying products.[3] It does not function as a general registry of excipients.

This has several consequences:

1. MSG itself does not receive Orange Book patent listings.
2. There is no standalone MSG Paragraph IV pathway.
3. A generic company would not challenge MSG as an active ingredient.
4. Patent disputes would normally concern the finished drug, formulation, manufacturing process, or method of treatment.
5. Excipient suppliers do not receive Hatch-Waxman exclusivity for selling MSG.

If an approved drug uses MSG as an inactive ingredient, any listed patent would ordinarily protect the drug product, formulation, method of use, or delivery system rather than the commodity excipient.

What patents protect monosodium glutamate?

The core MSG molecule is old and cannot support meaningful composition-of-matter exclusivity. The principal intellectual-property opportunities are process, purification, crystal form, formulation, packaging, and application patents.

IP category	Likely protection	Commercial strength
Composition of matter	MSG molecule	Effectively unavailable because of age
Fermentation strain	Engineered microorganism or production strain	Moderate where trade secrets and process control are strong
Fermentation process	Feedstock, pH, oxygenation, recovery, yield improvement	Moderate, but design-around risk is high
Purification	Decolorization, impurity removal, crystallization	Moderate
Crystal engineering	Particle size, morphology, flow, dissolution	Low to moderate
Pharmaceutical formulation	Taste masking, stability, nutrition, delivery	Product-specific
Manufacturing know-how	Yield, energy use, waste reduction, quality consistency	Often more valuable as trade secret than patent
Packaging and logistics	Moisture control and contamination prevention	Low

The strongest defensible assets are usually manufacturing know-how, validated supply systems, customer qualification, and quality documentation. Patents can protect selected process improvements, but generic MSG production is difficult to shield from competition because the molecule, fermentation concept, and basic recovery methods are widely known.

No broadly recognized patent estate appears to create monopoly control over pharmaceutical-grade MSG as a commodity. A buyer should treat supplier claims of "patented MSG" as potentially referring to a narrow process or formulation patent, not exclusive control of the ingredient.

When does monosodium glutamate lose exclusivity?

MSG has no practical exclusivity cliff comparable to an innovative drug. The molecule entered commercial use decades ago, and competing producers operate globally.

A relevant exclusivity timeline is:

Event	Approximate status
Discovery and early commercial production	Early to mid-20th century
Large-scale microbial fermentation	Established for decades
Food regulatory acceptance	Long established in major markets
Pharmaceutical-grade supply	Available from multiple international producers
Core molecule exclusivity	Expired or unavailable
Process patents	Potentially active only for specific techniques
Finished-drug exclusivity	Depends on the drug product, not MSG

There is no single patent expiration date that determines generic MSG entry. New suppliers can enter by producing a conforming material and completing customer qualification, subject to local regulatory and quality requirements.

How many companies manufacture pharmaceutical-grade MSG?

The number depends on the definition of "pharmaceutical-grade." Many producers manufacture MSG to food or industrial specifications, but fewer maintain the documentation, quality systems, regulatory support, and batch consistency expected by pharmaceutical customers.

Important commercial participants include:

Company	Geographic base	Relevant capabilities
Ajinomoto Co., Inc.	Japan and global	MSG, amino acids, pharmaceutical and bioprocessing materials
Fufeng Group	China	Large-scale MSG and amino-acid fermentation
Meihua Holdings	China	Amino acids, fermentation products, bioprocessing inputs
CJ CheilJedang	South Korea and global	Amino acids and fermentation-derived ingredients
Vedan International	Vietnam and Asia	MSG and fermentation products
Regional Chinese producers	China	High-volume commodity MSG

Ajinomoto has the strongest pharmaceutical and life-science brand positioning among the major MSG-linked suppliers. Chinese producers generally have greater scale and lower manufacturing costs, while multinational suppliers may compete through quality systems, technical support, geographic redundancy, and customer qualification history.

The supply base is more concentrated than the number of brand names suggests because upstream fermentation capacity, carbohydrate feedstock access, utilities, and crystallization infrastructure create significant operating advantages.

What drives the financial trajectory of the MSG excipient market?

The financial trajectory is determined more by volume, price, yield, and energy costs than by patent pricing power.

Volume drivers

Demand can increase through:

• Growth in oral liquid and taste-masked medicines
• Expansion of amino-acid and medical-nutrition products
• Greater use of fermentation-based manufacturing
• Growth in biologics and cell-culture supply chains
• Increased demand for high-purity excipients from emerging-market manufacturers
• Product reformulation away from more expensive specialty ingredients

Pharmaceutical demand is unlikely to become the primary volume driver. Food, seasoning, animal nutrition, and industrial fermentation remain much larger markets.

Cost drivers

The main input costs are:

• Corn, sugar, cassava, or other carbohydrate feedstocks
• Electricity and steam
• Fermentation nutrients
• Sulfuric acid, hydrochloric acid, and other processing chemicals
• Labor and environmental compliance
• Freight and packaging
• Wastewater treatment

MSG production is energy-intensive. Margin expansion depends on fermentation yield, plant utilization, energy procurement, recovery rates, and the ability to monetize co-products.

Pricing structure

MSG is generally a negotiated bulk product. Pharmaceutical-grade material can command a premium over food-grade material, but the premium is constrained by:

• Multiple qualified suppliers
• Low formulation quantities in many products
• Customer ability to validate alternative amino acids
• Limited differentiation in the core molecule
• Long-term supply contracts
• Regulatory costs of changing suppliers

The largest premium opportunity is not the chemical itself. It is the package of GMP production, audit readiness, change-control discipline, regulatory support, sterility-related controls where relevant, and reliable global supply.

What is the financial outlook for companies exposed to MSG?

Public financial reporting does not usually isolate pharmaceutical MSG revenue. Ajinomoto reports broader food products, amino acids, healthcare, and specialty businesses rather than a separately audited pharmaceutical MSG segment. Fufeng, Meihua, CJ CheilJedang, and Vedan also report broader product categories that combine MSG with amino acids, fermentation products, food ingredients, and related materials.

The expected financial pattern is therefore:

Period	Financial expectation
Near term	Volume growth with volatile margins caused by feedstock, energy, and China export pricing
Medium term	Stable-to-moderate growth in specialty and pharmaceutical-quality grades
Longer term	Margin differentiation through bioprocessing, amino-acid portfolios, and quality-certified supply
Downside case	Commodity oversupply, lower food demand, weak export pricing, and higher environmental costs
Upside case	Greater use in medical nutrition, biomanufacturing, and regulated high-purity applications

The pharmaceutical-grade segment should have better gross margins than commodity food MSG, but it is unlikely to produce drug-like margins. Qualification cycles can be long, yet annual consumption per customer may be modest. The economic value comes from customer retention and portfolio cross-selling rather than exclusivity.

How does MSG compare with competing pharmaceutical excipients?

MSG competes with other amino acids, salts, and taste-modifying ingredients.

Alternative	Relative advantage	Relative limitation
Glycine	Broad pharmaceutical use and established compendial history	Different taste, buffering, and stability profile
L-glutamic acid	Similar biological identity	Lower solubility and different pH behavior
Potassium glutamate	Lower sodium contribution	Potassium load and less common supply base
Sodium chloride	Low cost and familiar salt profile	Less effective for certain taste-masking strategies
Aspartame or sucralose	Strong sweetening performance	Different regulatory and formulation constraints
Citric acid salts	Buffering and taste modification	Different acidity and compatibility behavior
Hydrolyzed proteins	Complex flavor profile and nutrient value	Higher impurity and variability risk

MSG is most defensible where its flavor profile, amino-acid function, solubility, and manufacturing compatibility solve a specific formulation problem. It is weak as a premium excipient when the customer needs only a low-cost sodium source or generic taste modifier.

What generic-entry risks exist for MSG-containing medicines?

Generic-entry risk is high when MSG is used as a conventional inactive ingredient and does not materially determine product performance. A generic manufacturer can often use the same excipient, a pharmaceutically equivalent alternative, or a different taste-masking system.

Risk is lower where MSG contributes to:

• A proprietary taste-masking architecture
• A clinically relevant nutrition profile
• Stability of a biologic or peptide
• A specific injectable or parenteral process
• A patented combination of amino acids
• A formulation with narrow pH or osmolality requirements

For finished drugs, the relevant protections are formulation and method-of-use patents. MSG itself is not a barrier to generic entry.

What litigation and settlement activity affects MSG?

There is no widely established Orange Book litigation or major Paragraph IV settlement market centered on MSG as an excipient. Litigation risk is more likely to arise from:

• Supplier contract disputes
• Contamination or out-of-specification claims
• Supply interruption
• Misuse of process patents
• Trade-secret disputes involving fermentation strains
• Product-liability claims tied to finished formulations
• Regulatory enforcement involving labeling or quality systems

A pharmaceutical buyer should conduct freedom-to-operate review at the finished-product and manufacturing-process level. A standalone MSG patent search is unlikely to identify the principal commercial risks.

What manufacturing and geographic barriers affect supply?

China has major advantages in fermentation scale, feedstock access, production infrastructure, and export capacity. Japan and South Korea have stronger positioning in specialty amino acids, pharmaceutical quality, and technical support. Vietnam is an important regional production base.

Geographic risks include:

• Export controls or customs disruption
• Port congestion
• Energy-price shocks
• Environmental restrictions on fermentation plants
• Water availability
• Dependence on regional carbohydrate feedstocks
• Customer concentration
• Qualification delays for alternate sites

Manufacturing barriers are operational rather than technological. A new producer must demonstrate consistent fermentation performance, impurity control, particle-size reproducibility, documentation, and change management. Pharmaceutical customers may require site audits, quality agreements, multiple commercial batches, and stability data before approval.

Key Takeaways

• MSG is a mature, globally available molecule with no meaningful composition-of-matter exclusivity.
• Its pharmaceutical role is selective and smaller than its food, nutrition, and industrial applications.
• Pharmaceutical-grade value comes from quality systems, documentation, supply reliability, and technical support.
• China dominates production scale; Ajinomoto has the strongest specialty and life-science positioning.
• Public companies do not generally disclose pharmaceutical MSG revenue separately.
• Financial performance is driven by fermentation yield, feedstock prices, energy, capacity utilization, and export pricing.
• There is no standalone Orange Book, Paragraph IV, biosimilar, or drug-exclusivity framework for MSG.
• The most material IP is found in fermentation processes, purification, formulation, and trade secrets.
• Generic-entry risk is high when MSG is an ordinary inactive ingredient and lower when it supports a protected formulation or manufacturing process.
• The best long-term margin opportunity is in regulated amino-acid and bioprocessing products, not commodity MSG.

FAQs

Is monosodium glutamate approved for use in injectable drugs?

Use in an injectable product depends on the specific formulation, route, grade, impurity profile, endotoxin controls, and regulatory submission. Food approval alone does not establish suitability for injection.

Does MSG require a drug master file?

A drug master file may be useful for confidential manufacturing information, but it is not automatically required for every excipient. The sponsor, regulator, and supplier determine the appropriate regulatory submission structure.

Can pharmaceutical manufacturers switch MSG suppliers?

Yes, but a supplier change may require comparative testing, regulatory assessment, stability work, quality-agreement updates, and customer approval. The burden depends on dosage form and route.

Is pharmaceutical MSG more expensive than food-grade MSG?

Usually, pharmaceutical-quality material carries a premium because of documentation, testing, GMP controls, audit requirements, and lower production volumes. The premium varies by specification and contract.

Does MSG create sodium-related formulation risk?

Yes. MSG contributes sodium and may affect osmolality, electrolyte load, labeling, and suitability for sodium-restricted products. The risk must be assessed against the total formulation composition.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 182: Substances generally recognized as safe.
2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. Food Chemicals Codex. (2024). Food Chemicals Codex. United States Pharmacopeial Convention.
6. Ajinomoto Co., Inc. (2024). Integrated report 2024.
7. Fufeng Group Limited. (2024). Annual report 2023.
8. Meihua Holdings Group Co., Ltd. (2024). Annual report 2023.
9. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia.